Top 20 of Candidiasis

Article title # Publications/# Citations

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

2004: TBischoff; MBEdmond; HSeifert; SMTallent; RPWenzel; HWisplinghoff;

485

Epidemiology of invasive candidiasis: a persistent public health problem.

2007: DJDiekema; MAPfaller;

409

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

2009: Infectious Diseases Society of America; DAndes; DKBenjamin; TFCalandra; JEEdwards; SGFiller; JFFisher; CAKauffman; ... BJKullberg; LOstrosky-Zeichner; PGPappas; ACReboli; JHRex; JDSobel; TJWalsh;

322

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1998: RABowden; KAMarr; TCWhite;

245

Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

1981: PTFan; MSGottlieb; ASaxon; HMSchanker; RSchroff; JDWeisman; RAWolf;

243

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

2001: Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases; SAscioglu; JEBennett; JBille; FCrokaert; BDe Pauw; DWDenning; ... JPDonnelly; JEEdwards; ZErjavec; DFière; OLortholary; JMaertens; JFMeis; TFPatterson; JHRex; JRitter; DSelleslag; PMShah; DAStevens; TJWalsh;

223

Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice.

2004: PLFidel; WHuang; LNa; PSchwarzenberger;

221

Killing activity of neutrophils is mediated through activation of proteases by K+ flux.

2002: SBolsover; GGabella; HLJacobs; HLu; CGMessina; EOPotma; EPReeves; JRoes; AWSegal; AWarley;

210

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

1997: ALBarry; MSBartlett; AEspinel-Ingroff; JNGalgiani; MAGhannoum; MLancaster; FCOdds; MAPfaller; ... JHRex; MGRinaldi; TJWalsh;

198

Dectin-1 is required for beta-glucan recognition and control of fungal infection.

2006: MBotto; GDBrown; KMDennehy; HFindon; SGordon; KHaynes; MRosas; CSteele; ... PRTaylor; SVTsoni; JAWillment;

188

Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

2001: JChandra; MAGhannoum; LLHoyer; DMKuhn; TMcCormick; PKMukherjee;

184

An integrated model of the recognition of Candida albicans by the innate immune system.

2008: GDBrown; NAGow; BJKullberg; MGNetea;

178

Attributable mortality of nosocomial candidemia, revisited.

2003: DDiekema; SGillespie; OGudlaugsson; LHerwaldt; JHu; KLee; SMesser; MPfaller; JVande Berg;

171

Resistance of Candida species to fluconazole.

1995: MAPfaller; JHRex; MGRinaldi;

165

Virulence factors of Candida albicans.

2001: RACalderone; WAFonzi;

158

Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection.

2003: ALLazzell; JLLopez-Ribot; CMonteagudo; SPSaville;

156

Toll-like receptor 2 controls expansion and function of regulatory T cells.

2006: GJAdema; SAkira; EJBennink; MHDen Brok; LAJoosten; MKramer; BJKullberg; MGNetea; RPSutmuller; LWToonen;

153

Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3.

2008: GYChew; MCCook; DAFulcher; BGrimbacher; CSMa; APriyadarshi; NSimpson; SGTangye; MWong;

144

Putative virulence factors of Candida albicans.

1991: JECutler;

143

Yeast-enhanced green fluorescent protein (yEGFP): a reporter of gene expression in Candida albicans.

1997: GBertram; AJBrown; BPCormack; MEgerton; SFalkow; NAGow;

143